Drug Database
Back to search

Poland· PL-100368524

Metamizole Kalceks

A metamizole sodium product containing metamizolum natricum monohydricum, registered in Poland by AS Kalceks. The same ATC class is registered in 8 of our 19 countries.

ATC N02BB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedMetamizole KalceksATCN02BB02REGISTER NO.PL-100368524PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about metamizolum natricum monohydricumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Metamizole sodium is registered in 8 of 19 countries.

Countries holding a registration under ATC N02BB02 (metamizole sodium), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search metamizole sodium products by name

Metamizole sodium · ATC N02BB02

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of metamizole sodium costs, country by country.

Normalised to the WHO defined daily dose (3 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Metamizole sodium · price per daily dose (3 g)

USD · FX 28 Sept 2026

  • CH Switzerland$3.00
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Metamizolum natricum monohydricum
Manufacturer
AS Kalceks
Country
Poland (PL)
ATC code
N02BB02
ATC class
Metamizole sodium
Defined daily dose
3 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    04750341001490
  • gtin
    04750341001506
  • gtin
    04750341001421
  • gtin
    04750341001438
  • gtin
    04750341001520
  • gtin
    04750341001513

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for metamizole sodium.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check metamizole sodium against other medicinesHow interaction checks work

Metamizole sodium · interactions on record

5 records

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Metamizole sodium in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metamizole sodium products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Novalgine
  • Bulgaria · Аналгин, Аналгин За Деца
  • Germany · Metamizol Ratiopharm, Novaminsulfon
  • Spain · Algi-Mabo, Metalgial
  • Hungary · Algopyrin, Algozone
  • Italy · Metamizolo Sodico Abc, Novalgina
  • Lithuania · Analgin, Analginas
  • Luxembourg · Novalgine
  • Latvia · Analgin, Metamizole Sodium Kalceks
  • Portugal · Metamizol Chalim, Metamizol Magnésico Tolife
  • Romania · Alindor, Centralgin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b4ca8805-e68e-4705-a49b-4fddda4c4f95
GET /v1/drugs/b4ca8805-e68e-4705-a49b-4fddda4c4f95?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "500 mg/ml",
  "packaging": "04750341001490 ¦ Rp ¦ 123569\n5 amp. 2 ml\n04750341001506 ¦ Rp ¦ 123570\n5 amp. 5 ml\n04750341001421 ¦ Rp ¦ 123571\n10 amp. 2 ml\n04750341001438 ¦ Rp ¦ 123572\n10 amp. 5 ml\n04750341001520 ¦ Rp ¦ 123573\n100 amp. 5 ml\n04750341001513 ¦ Rp ¦ 123574\n100 amp. 2 ml",
  "substance": "Metamizolum natricum monohydricum 500 mg/ml",
  "common_name": "Metamizolum natricum monohydricum",
  "pl_product_id": "100368524",
  "pozwolenie_nr": "24140",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about metamizole sodium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console